ARS Pharmaceuticals Ownership | Who Owns ARS Pharmaceuticals?
ARS Pharmaceuticals Ownership Summary
ARS Pharmaceuticals is owned by 70.34% institutional investors, 23.84% insiders, and 5.83% retail investors. Ra capital management is the largest institutional shareholder, holding 11.19% of SPRY shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.03% of its assets in ARS Pharmaceuticals shares.
SPRY Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | ARS Pharmaceuticals | 70.34% | 23.84% | 5.83% |
| Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
| Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Ra capital management | 10.86M | 11.19% | $114.58M |
| Deerfield management company, l.p. (series c) | 10.51M | 10.84% | $110.93M |
| Orbimed advisors | 8.29M | 8.54% | $87.44M |
| Blackrock funding, inc. /de | 4.57M | 4.71% | $48.26M |
| Sr one capital management, lp | 4.01M | 4.14% | $42.34M |
| Alliancebernstein | 3.88M | 4.00% | $40.94M |
| Vanguard group | 3.46M | 3.57% | $36.56M |
| Franklin resources | 1.98M | 2.04% | $20.85M |
| Alyeska investment group | 1.25M | 1.29% | $13.23M |
| Geode capital management | 1.24M | 1.28% | $13.07M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Sr one capital management, lp | 4.01M | 10.32% | $42.34M |
| Deerfield management company, l.p. (series c) | 10.51M | 2.10% | $110.93M |
| Orbimed advisors | 8.29M | 1.81% | $87.44M |
| Nextech invest | 936.73K | 1.60% | $9.88M |
| Ra capital management | 10.86M | 1.52% | $114.58M |
| First turn management | 593.29K | 1.12% | $6.26M |
| Sectoral asset management | 106.01K | 0.75% | $1.12M |
| Wexford capital lp | 369.50K | 0.62% | $3.90M |
| Levin capital strategies | 467.63K | 0.47% | $4.93M |
| Valley forge investment consultants inc adv | 83.22K | 0.30% | $878.02K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Alliancebernstein | 3.88M | 0.01% | 3.81M |
| Alyeska investment group | 1.25M | 0.05% | 1.13M |
| Ubs group | 1.01M | 0.00% | 902.82K |
| Raymond james financial | 623.28K | 0.00% | 623.28K |
| Goldman sachs group | 886.12K | 0.00% | 610.26K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Franklin resources | 1.98M | 0.01% | -860.84K |
| Deerfield management company, l.p. (series c) | 10.51M | 2.10% | -563.27K |
| Duquesne family office | - | - | -536.90K |
| Price t rowe associates inc /md/ | 19.92K | - | -442.60K |
| Eam investors | - | - | -261.65K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Raymond james financial | 623.28K | 0.00% | 623.28K | $6.58M |
| Cormorant asset management, lp | 500.00K | 0.29% | 500.00K | $5.28M |
| Peregrine capital management | 423.56K | 0.13% | 423.56K | $4.47M |
| Bank of montreal /can/ | 340.59K | 0.00% | 340.59K | $3.59M |
| Sei investments | 108.27K | 0.00% | 108.27K | $1.14M |
Sold Out
| Holder | Change |
|---|---|
| National bank of canada /fi/ | -1.00 |
| Srs capital advisors | -22.00 |
| Capital performance advisors llp | -33.00 |
| Acadian asset management | -4.01K |
| Quarry lp | -12.00K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 164 | 1.23% | 68,247,890 | 6.54% | 70 | 1.61% | 88 | -14.56% | 44 | 69.23% |
| Sep 30, 2024 | 162 | 35.00% | 64,056,669 | 2.41% | 66 | 1.58% | 103 | 51.47% | 26 | 8.33% |
| Jun 30, 2024 | 120 | 1.69% | 62,551,055 | 4.44% | 64 | 1.68% | 68 | 3.03% | 24 | -4.00% |
| Mar 31, 2024 | 118 | 12.38% | 59,892,346 | -8.46% | 62 | 1.35% | 66 | 37.50% | 25 | -16.67% |
| Dec 31, 2023 | 105 | -0.94% | 65,425,953 | -1.66% | 67 | 1.40% | 48 | -20.00% | 30 | 30.43% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.99M | 2.03% | - |
| Vanguard US Total Market Shares ETF | 1.86M | 1.90% | - |
| Franklin Biotechnology Discv A(acc)USD | 1.41M | 1.44% | 115.06K |
| iShares Russell 2000 ETF | 1.30M | 1.33% | -11.28K |
| AB Small Cap Growth A | 1.16M | 1.19% | -30.98K |
| Fidelity Select Biotechnology | 1.01M | 1.03% | -70.90K |
| MEDICAL BioHealth EUR Acc | 952.47K | 0.97% | -314.40K |
| SPDR® S&P Biotech ETF | 922.77K | 0.94% | -9.88K |
| Franklin Biotechnology Discovery A | 801.48K | 0.82% | 53.31K |
| Vanguard Institutional Extnd Mkt Idx Tr | 787.19K | 0.80% | 9.75K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Apr 07, 2025 | Shawver Laura | - | Sell | $615.07K |
| Mar 20, 2025 | Karas Eric | Chief Commercial Officer | Sell | $140.00K |
| Mar 06, 2025 | Shawver Laura | - | Sell | $556.05K |
| Mar 05, 2025 | Shawver Laura | - | Sell | $4.40K |
| Feb 03, 2025 | Shawver Laura | - | Sell | $615.57K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | - | 1 |
| 2025 Q1 | - | 5 |
| 2024 Q4 | - | 58 |
| 2024 Q3 | - | 51 |
| 2024 Q2 | - | 32 |
SPRY Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools